Division of Pediatric Critical Care Medicine, Children's Hospital of Richmond at VCU, Richmond, Virginia.
Pediatric Critical Care Medicine, NY Presbyterian Hospital - Weill Cornell Medicine, New York, New York.
Transfusion. 2021 Mar;61(3):660-664. doi: 10.1111/trf.16272. Epub 2021 Jan 25.
Due to the patients' underlying illness, in combination with circuit-induced coagulopathy, as well as PLT dysfunction, children supported by ECMO are a risk of receiving large volumes of blood components. Given the increasing use of modified blood products and newer biologics, it is unknown whether these products have equal efficacy and safety, in ECMO. The majority of guidance for transfusion therapy is based on expert opinion alone, and research on indications for RBC, plasma, and PLT transfusions for children on ECMO should be a priority.
由于患者的基础疾病，再加上回路诱导的凝血病以及血小板功能障碍，接受 ECMO 支持的儿童有接受大量血液成分的风险。鉴于改良血液制品和新型生物制剂的使用越来越多，尚不清楚这些产品在 ECMO 中的疗效和安全性是否相同。输血治疗的大多数指南仅基于专家意见，应优先研究 ECMO 患儿红细胞、血浆和血小板输注的适应证。
